Search - tctmd.com

Displaying 441 - 460 of 1731

Sort: Relevancy | Date

Presentation TCT 2019

Industry Perspective on Drug-Eluting Technologies Guidance

Presenter: Mark Pacyna

September 25, 2019

Presentation TCT 2019

TCT 41: A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial

Presenter: Azfar Zaman

September 25, 2019

Presentation TCT 2019

FDA Perspective and Revised Guidance

Presenter: Eleni Whatley

September 25, 2019

Presentation TCT 2019

New Data Regarding Drug-Eluting Technologies

Presenter: Krishna Rocha-Singh

September 25, 2019

Presentation TCT 2019

An Unforeseen Setback: Summary Level Meta-Analysis Brings Practice Back to the 1990s.

Presenter: Michael Jaff

September 25, 2019

Presentation TCT 2019

Case Example: Contemporary DES Thrombosis

Presenter: Amir Darki

September 25, 2019

Presentation TCT 2019

Drug-Eluting Stent Thrombosis and Restenosis: Mechanisms, Frequency, and Treatment

Presenter: Binita Shah

September 25, 2019

Presentation TCT 2019

Case Example: Complex DES With Long-Term Outcomes

Presenter: Anita Paggi

September 25, 2019

Presentation TCT 2019

Drug-Eluting Stent Platforms and Outcomes 2019

Presenter: Roberto Diletti

September 25, 2019

Presentation TCT 2019

Drug-Coated Balloons: State of the Art in the Face of Controversy

Presenter: Antonio Colombo

September 25, 2019

Even With PSP, Bioresorbable Scaffold Falls Short in ABSORB-COMPARE and ABSORB IV Trials

News Conference News TCT 2018

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

Michael O'Riordan

September 25, 2018

News Opinion Editor's Corner TCT 2018

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

Shelley Wood

September 25, 2018

Presentation TCT 2018

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

Presenter: James B. Hermiller Jr, Hiroki Shiomi

September 25, 2018

News Conference News TCT 2018

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

Michael O'Riordan

September 25, 2018

Presentation TCT 2018

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

Presenter: Felix Mahfoud, Patrick W. Serruys, Pieter C. Smits

September 25, 2018

Presentation TCT 2018

ABSORB IV: A Blinded Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in an Expanded Patient Population Using Optimized Technique

Presenter: Felix Mahfoud, Patrick W. Serruys, Gregg W. Stone

September 25, 2018

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

Presentation TCT 2018

MAIN-COMPARE: Ten-Year Follow-up From a Nonrandomized Trial of Drug-Eluting Stents vs Bypass Surgery in Patients With Left Main Disease

Presenter: Jeroen J. Bax, Seung-Jung Park

September 24, 2018

Presentation TCT 2018

SYNTAXES: Ten-Year Follow-up From a Randomized Trial of Drug-Eluting Stents vs Bypass Surgery in Patients With Left Main and Triple Vessel Disease (Preliminary Results)

Presenter: Jeroen J. Bax, Daniel J.F.M. Thuijs

September 24, 2018

Presentation TCT 2018

PREPARE-CALC: A Randomized Trial of High-speed Rotational Atherectomy Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions

Presenter: Jeroen J. Bax, Gert Richardt

September 24, 2018

Advertisement

Industry Perspective on Drug-Eluting Technologies Guidance

TCT 41: A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial

FDA Perspective and Revised Guidance

New Data Regarding Drug-Eluting Technologies

An Unforeseen Setback: Summary Level Meta-Analysis Brings Practice Back to the 1990s.

Case Example: Contemporary DES Thrombosis

Drug-Eluting Stent Thrombosis and Restenosis: Mechanisms, Frequency, and Treatment

Case Example: Complex DES With Long-Term Outcomes

Drug-Eluting Stent Platforms and Outcomes 2019

Drug-Coated Balloons: State of the Art in the Face of Controversy

Even With PSP, Bioresorbable Scaffold Falls Short in COMPARE-ABSORB and ABSORB IV Trials

TCT 2018, Day Four: Bioresorbable Scaffolds, Renal Denervation, Head-to-Head TAVR, INOCA, and . . . That’s a Wrap!

RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease

PCI vs CABG at 10 Years: MAIN-COMPARE and SYNTAXES Shine Light on Long-term Outcomes

COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions

ABSORB IV: A Blinded Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in an Expanded Patient Population Using Optimized Technique

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

MAIN-COMPARE: Ten-Year Follow-up From a Nonrandomized Trial of Drug-Eluting Stents vs Bypass Surgery in Patients With Left Main Disease

SYNTAXES: Ten-Year Follow-up From a Randomized Trial of Drug-Eluting Stents vs Bypass Surgery in Patients With Left Main and Triple Vessel Disease (Preliminary Results)

PREPARE-CALC: A Randomized Trial of High-speed Rotational Atherectomy Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content